Trial Profile
Can local intramuscular botulinum toxin improve dysphagia in patients with myopathic dysphagia and constriction of the cricoid muscle?
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Deglutition disorders; Inclusion body myositis; Oculopharyngeal muscular dystrophy
- Focus Therapeutic Use
- 01 Aug 2022 Results published in the Journal of Neurology
- 08 Apr 2019 Status changed from recruiting to completed.
- 06 Jan 2015 New trial record